

Thomas S Stroup

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3890970/thomas-s-stroup-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

32,081
citations

67
h-index

179
g-index

196
ext. papers

38,217
ext. citations

8.9
avg, IF

7.9
L-index

#	Paper	IF	Citations
185	Feasibility and Utility of Different Approaches to Violence Risk Assessment for Young Adults Receiving Treatment for Early Psychosis.. <i>Community Mental Health Journal</i> , 2022 , 1	2.1	2
184	An international survey examining the impact of the COVID-19 pandemic on telehealth use among mental health professionals.. <i>Journal of Psychiatric Research</i> , 2022 , 148, 188-196	5.2	3
183	Mapping genomic loci implicates genes and synaptic biology in schizophrenia.. <i>Nature</i> , 2022 ,	50.4	35
182	Violence risk assessment for young adults receiving treatment for early psychosis. <i>International Journal of Law and Psychiatry</i> , 2021 , 76, 101701	2.6	3
181	Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2021 , 78, 632-641	14.5	10
180	Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. <i>JAMA Psychiatry</i> , 2021 , 78, 876-885	14.5	7
179	Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. <i>Psychiatric Services</i> , 2021 , appips202000932	3.3	4
178	Generating comparative evidence on new drugs and devices before approval. <i>Lancet, The</i> , 2020 , 395, 986-997	40	28
177	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020 , 220, 92-97	3.6	1
176	Mortality risk of antipsychotic augmentation for adult depression. <i>PLoS ONE</i> , 2020 , 15, e0239206	3.7	7
175	Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. <i>Trials</i> , 2020 , 21, 871	2.8	0
174	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019 , 208, 182-189	3.6	12
173	Examination of heterogeneity in treatment response to antipsychotic medications. <i>Schizophrenia Research</i> , 2019 , 211, 100-102	3.6	
172	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , 2019 , 4,	1.7	3
171	Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019 , 76, 508-515	14.5	23
170	Deaths of people with mental illness during interactions with law enforcement. <i>International Journal of Law and Psychiatry</i> , 2018 , 58, 110-116	2.6	28
169	Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. <i>Psychiatric Services</i> , 2018 , 69, 605-608	3.3	2

168	Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	11
167	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. <i>Journal of Clinical Psychiatry</i> , 2018 , 80,	4.6	3
166	Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i> , 2018 , 17, 341-354	14.4	146
165	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018 , 102, 1185-1194	11	55
164	Raising the standard of care for schizophrenia is an achievable goal. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017 , 51, 637-638	2.6	
163	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017 , 49, 27-35	36.3	530
162	Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits. <i>Current Behavioral Neuroscience Reports</i> , 2016 , 3, 165-175	1.7	27
161	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016 , 67, 1124-1130	3.3	9
160	Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. <i>American Journal of Psychiatry</i> , 2016 , 173, 166-73	11.9	106
159	Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. <i>Psychiatric Services</i> , 2016 , 67, 152	3.3	17
158	An Initiative to Improve Clozapine Prescribing in New York State. <i>Psychiatric Services</i> , 2016 , 67, 369-71	3.3	23
157	Effectiveness of long-acting injectable antipsychotics: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2015 , 18, 36-9	11.1	22
156	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015 , 97, 576-92	11	649
155	Premature Mortality Among Adults With Schizophrenia in the United States. <i>JAMA Psychiatry</i> , 2015 , 72, 1172-81	14.5	535
154	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015 , 44, 1706-21	7.8	43
153	Electronic health records in mental health research: a framework for developing valid research methods. <i>Psychiatric Services</i> , 2015 , 66, 193-6	3.3	11
152	LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. <i>Nature Genetics</i> , 2015 , 47, 291-5	36.3	2096
151	Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. <i>American Journal of Human Genetics</i> , 2014 , 95, 535-52	11	411

150	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014 , 511, 421-7	50.4	5249
149	Response to Rosenfeld. <i>American Journal of Psychiatry</i> , 2014 , 171, 119-20	11.9	
148	Geographic and clinical variation in clozapine use in the United States. <i>Psychiatric Services</i> , 2014 , 65, 186-92	3.3	75
147	Tobacco use and mental illness: a wake-up call for psychiatrists. <i>Psychiatric Services</i> , 2014 , 65, 1406-8	3.3	24
146	A multiple imputation strategy for sequential multiple assignment randomized trials. <i>Statistics in Medicine</i> , 2014 , 33, 4202-14	2.3	32
145	Antipsychotic medications for schizophrenia--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1469	27.4	
144	Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1978-87	27.4	107
143	What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 1261-2	4.6	4
142	Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. <i>Schizophrenia Bulletin</i> , 2013 , 39, 564-74	1.3	90
141	The need to determine the best options for people with schizophrenia that is unresponsive to treatment. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013 , 6, 1-3	0.2	
140	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013 , 45, 984-94	36.3	1628
139	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013 , 146, 190-5	3.6	24
138	Drug information update: paliperidone palmitate for schizophrenia. <i>The Psychiatrist</i> , 2013 , 37, 164-166		2
137	Public-academic partnerships: a rapid small-grant program for policy-relevant research: motivating public-academic partnerships. <i>Psychiatric Services</i> , 2013 , 64, 106-8	3.3	1
136	Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. <i>American Journal of Psychiatry</i> , 2013 , 170, 1032-40	11.9	94
135	Polypharmacy for schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013 , 26, 208-13	4.9	42
134	The enduring challenge of antipsychotic non-adherence. <i>World Psychiatry</i> , 2013 , 12, 236-7	14.4	1
133	Schizophrenia genetic variants are not associated with intelligence. <i>Psychological Medicine</i> , 2013 , 43, 2563-70	6.9	34

132	Paliperidone palmitate for schizophrenia. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1124-7	1.3	16
131	Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. <i>Psychiatric Services</i> , 2012 , 63, 1146-9	3.3	20
130	Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i>Pharmacogenomics Journal</i> , 2012 , 12, 165-72	3.5	61
129	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>Focus (American Psychiatric Publishing)</i> , 2012 , 10, 226-230	1.1	1
128	Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 669-75	4.6	43
127	Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 1016-22	4.6	68
126	Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 526-32	4.6	60
125	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011 , 43, 969-76	36.3	1508
124	The association between weight change and symptom reduction in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2011 , 128, 166-70	3.6	57
123	Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. <i>Schizophrenia Research</i> , 2011 , 130, 47-52	3.6	27
122	Substance use and schizophrenia: adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011 , 132, 177-82	3.6	46
121	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). <i>Frontiers in Genetics</i> , 2011 , 2, 56	4.5	15
120	Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 266-73	1.7	28
119	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011 , 16, 76-85	15.1	124
118	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011 , 16, 321-32	15.1	123
117	Criminal justice system involvement among people with schizophrenia. <i>Community Mental Health Journal</i> , 2011 , 47, 727-36	2.1	8
116	Informing sequential clinical decision-making through reinforcement learning: an empirical study. <i>Machine Learning</i> , 2011 , 84, 109-136	4	72
115	Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i>Journal of Community Psychology</i> , 2011 , 39, 76-88	2.2	18

114	The NIMH-CATIE Schizophrenia Study: what did we learn?. <i>American Journal of Psychiatry</i> , 2011 , 168, 770-5	11.9	75
113	Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 1587-91	2.9	16
112	Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. <i>Neuropsychopharmacology</i> , 2011 , 36, 616-26	8.7	87
111	Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. <i>American Journal of Psychiatry</i> , 2011 , 168, 831-9	11.9	180
110	Effectiveness of switching from antipsychotic polypharmacy to monotherapy. <i>American Journal of Psychiatry</i> , 2011 , 168, 702-8	11.9	122
109	What can large simple trials do for psychiatry?. <i>American Journal of Psychiatry</i> , 2011 , 168, 117-9	11.9	8
108	A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). <i>American Journal of Psychiatry</i> , 2011 , 168, 947-56	11.9	123
107	Time to All-cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Statistics in Biopharmaceutical Research</i> , 2011 , 3, 253-265	1.2	12
106	No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differ. <i>Evidence-Based Mental Health</i> , 2011 , 14, 25	11.1	
105	Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. <i>Schizophrenia Bulletin</i> , 2011 , 37, 1057-65	1.3	60
104	Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 75-80	4.6	26
103	Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 295-303	4.6	39
102	Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2010 , 13, 53	11.1	
101	Genomewide association study of movement-related adverse antipsychotic effects. <i>Biological Psychiatry</i> , 2010 , 67, 279-82	7.9	107
100	A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 336-40	3.5	21
99	No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 1115-7	3.5	7
98	Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. <i>American Journal of Psychiatry</i> , 2009 , 166, 583-90	11.9	65
97	The impact of obesity on health care costs among persons with schizophrenia. <i>General Hospital Psychiatry</i> , 2009 , 31, 1-7	5.6	30

96	Microduplications of 16p11.2 are associated with schizophrenia. <i>Nature Genetics</i> , 2009 , 41, 1223-7	36.3	550
95	Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Biological Psychiatry</i> , 2009 , 66, 1013-22	7.9	81
94	Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. <i>Schizophrenia Research</i> , 2009 , 107, 22-9	3.6	135
93	Results of phase 3 of the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009 , 107, 1-12	3.6	106
92	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2009 , 113, 12-8	3.6	9
91	Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. <i>Schizophrenia Bulletin</i> , 2009 , 35, 336-46	1.3	198
90	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008 , 13, 570-84	15.1	308
89	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. <i>Schizophrenia Research</i> , 2008 , 100, 39-52	3.6	45
88	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. <i>Schizophrenia Research</i> , 2008 , 101, 273-86	3.6	222
87	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008 , 103, 104-9	3.6	59
86	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008 , 105, 175-87	3.6	179
85	Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. <i>Biological Psychiatry</i> , 2008 , 63, 32-41	7.9	54
84	Paliperidone for schizophrenia. <i>The Cochrane Library</i> , 2008 , CD006369	5.2	19
83	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008 , 193, 37-43	5.4	146
82	Relationship of cognition and psychopathology to functional impairment in schizophrenia. <i>American Journal of Psychiatry</i> , 2008 , 165, 978-87	11.9	149
81	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008 , 193, 279-88	5.4	200
80	What CATIE found: results from the schizophrenia trial. <i>Psychiatric Services</i> , 2008 , 59, 500-6	3.3	89
79	Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008 , 35, 215-25	1.7	17

78	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1298-300	3.5	24
77	Paliperidone for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2008 , 34, 419-22	1.3	13
76	Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. <i>Schizophrenia Bulletin</i> , 2008 , 34, 266-74	1.3	11
75	AKT1 and neurocognition in schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007 , 41, 169-77	2.6	12
74	NCAM1 and neurocognition in schizophrenia. <i>Biological Psychiatry</i> , 2007 , 61, 902-10	7.9	70
73	Determining when impairment constitutes incapacity for informed consent in schizophrenia research. <i>British Journal of Psychiatry</i> , 2007 , 191, 38-43	5.4	106
72	Risperidone versus olanzapine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2007 , 33, 1274-6	1.3	9
71	Drs. Stroup, Rosenheck, Essock, and Lieberman Reply. <i>American Journal of Psychiatry</i> , 2007 , 164, 1266-1267		2
70	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 103-11	2.2	20
69	Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007 , 64, 633-47		781
68	Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 428-36	11.9	212
67	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. <i>American Journal of Psychiatry</i> , 2007 , 164, 415-27	11.9	117
66	Cost-effectiveness of schizophrenia pharmacotherapy. <i>American Journal of Psychiatry</i> , 2007 , 164, 678; author reply 678-9	11.9	6
65	Heterogeneity of treatment effects in schizophrenia. <i>American Journal of Medicine</i> , 2007 , 120, S26-31	2.4	32
64	Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH Schizophrenia Trials Network Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007 , 1, 69-72	1.6	4
63	The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1751-62	4.6	184
62	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Psychiatric Publishing)</i> , 2006 , 4, 539-552	1.1	
61	Barriers to employment for people with schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 411-7	11.9	327

60	Vasodilators in aortic regurgitation. <i>New England Journal of Medicine</i> , 2006 , 354, 300-3; author reply 300-3	59.2	1
59	Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. <i>American Journal of Veterinary Research</i> , 2006 , 67, 1173-8	1.1	15
58	Baseline neurocognitive deficits in the CATIE schizophrenia trial. <i>Neuropsychopharmacology</i> , 2006 , 31, 2033-46	8.7	374
57	Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. <i>Evidence-Based Mental Health</i> , 2006 , 9, 70	11.1	1
56	A national study of violent behavior in persons with schizophrenia. <i>Archives of General Psychiatry</i> , 2006 , 63, 490-9		505
55	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-610	11.9	682
54	Effectiveness of switching antipsychotic medications. <i>American Journal of Psychiatry</i> , 2006 , 163, 2090-5	11.9	134
53	Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. <i>New England Journal of Medicine</i> , 2006 , 355, 1525-38	59.2	875
52	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006 , 86, 15-22	3.6	389
51	Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. <i>Psychiatric Services</i> , 2006 , 57, 1110-6	3.3	52
50	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-622	11.9	283
49	Dr. Lieberman and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006 , 163, 555-a-556	11.9	2
48	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. <i>American Journal of Psychiatry</i> , 2006 , 163, 2080-9	11.9	218
47	Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. <i>Journal of Nervous and Mental Disease</i> , 2006 , 194, 164-72	1.8	115
46	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006 , 60, 933-40	2.9	36
45	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 133-46	64.1	39
44	Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. <i>Schizophrenia Bulletin</i> , 2006 , 32, 147-52	1.3	11
43	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. <i>American Journal of Psychiatry</i> , 2006 , 163, 600-10	11.9	359

42	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , 2006 , 163, 611-22	11.9	153
41	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. <i>New England Journal of Medicine</i> , 2005 , 353, 1209-23	59.2	4423
40	Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005 , 80, 19-32	3.6	885
39	The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. <i>Schizophrenia Research</i> , 2005 , 80, 9-18	3.6	157
38	Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005 , 80, 33-43	3.6	119
37	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005 , 80, 1-8	3.6	72
36	A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. <i>Schizophrenia Research</i> , 2005 , 80, 45-53	3.6	406
35	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005 , 187, 529-36	5.4	68
34	Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus. <i>Hippocampus</i> , 2005 , 15, 97-103	3.5	82
33	Assessment of Medicaid managed behavioral health care for persons with serious mental illness. <i>Psychiatric Services</i> , 2005 , 56, 1245-53	3.3	39
32	Schizophrenia, drug therapy, and monitoring. <i>New England Journal of Medicine</i> , 2004 , 350, 415-6	59.2	1
31	Physical health monitoring of patients with schizophrenia. <i>American Journal of Psychiatry</i> , 2004 , 161, 1334-49	11.9	646
30	Revised PORT recommendations. <i>Schizophrenia Bulletin</i> , 2004 , 30, 609-11	1.3	2
29	The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 500-8	4.6	125
28	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. <i>Schizophrenia Bulletin</i> , 2003 , 29, 15-31	1.3	462
27	Guest editors Introduction: what can large pragmatic clinical trials do for public mental health care?. <i>Schizophrenia Bulletin</i> , 2003 , 29, 1-6	1.3	5
26	Schizophrenia, VI: Treatments. <i>American Journal of Psychiatry</i> , 2003 , 160, 1748	11.9	7
25	Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. <i>Schizophrenia Bulletin</i> , 2003 , 29, 33-43	1.3	91

24	Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs. <i>Psychiatric Services</i> , 2002 , 53, 293-8	3.3	13
23	Correlates of family burden under medicaid managed mental health care. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2001 , 29, 117-28	3.1	6
22	Causes of schizophrenia reported by patients/family members in China. <i>British Journal of Psychiatry</i> , 2000 , 177, 20-5	5.4	109
21	Drugs of the psychopharmacological revolution in clinical psychiatry. <i>Psychiatric Services</i> , 2000 , 51, 1254-83	3.3	16
20	Management of Medical Illness in Persons With Schizophrenia. <i>Psychiatric Annals</i> , 2000 , 30, 35-40	0.5	16
19	Clinical and Community-Service Activities of Psychiatric Teaching Hospitals. <i>Academic Psychiatry</i> , 1999 , 23, 123-127	1.1	
18	Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study80-96		
17	Family outcomes133-155		
16	Study design and protocol development process1-21		
15	Statistical considerations22-38		
14	Cost-effectiveness and cost-benefit analysis57-79		
13	Neurocognition97-119		2
12	Metabolic side effects and risk of cardiovascular disease173-188		
11	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome189-206		4
10	Violence in schizophrenia: prevalence, correlates, and treatment effectiveness207-236		1
9	Genetic investigations in the CATIE sample237-254		
8	Implications for research design and study implementation281-287		
7	Conclusion and implications for practice and policy288-306		

6 Human subjects considerations255-266

5 Effectiveness and efficacy: staying on treatment and symptom reduction39-56

4 Population pharmacokinetics of antipsychotics267-280

1

3 Vocational outcomes120-132

2 Extrapyramidal side effects156-172

1

1 Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia525-539